280 related articles for article (PubMed ID: 135367)
1. [Fibrinolytic system in patients with nephrotic syndrome].
Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
[No Abstract] [Full Text] [Related]
2. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome.
Gandrille S; Jouvin MH; Toulon P; Remy P; Fiessinger JN; Roncato M; Moatti N; Aiach M
Thromb Haemost; 1988 Jun; 59(3):445-50. PubMed ID: 3142081
[TBL] [Abstract][Full Text] [Related]
3. [Possibilities of early diagnosis of thromboembolic complications in myocardial infarct by means of biochemical methods].
Andreenko GV; Bessolitsyna LA; Sargin KE
Kardiologiia; 1977 Jan; 17(1):98-103. PubMed ID: 140260
[TBL] [Abstract][Full Text] [Related]
4. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P
Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037
[TBL] [Abstract][Full Text] [Related]
5. [Fibrinolytic properties of the blood of rheumatoid arthritis patients].
Erov NK
Lab Delo; 1986; (7):417-20. PubMed ID: 2429032
[No Abstract] [Full Text] [Related]
6. Plasminogen activator in nephrotic syndrome.
Andreenko GV; Podoroldskaya LV; Polyantseva LP
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):351-5. PubMed ID: 2465229
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of fibrinolysis in essential hypertension.
Ettenger MM; MacCarthy EP; Glas-Greenwalt P; Clyne DH; Pollak VE
J Hypertens Suppl; 1984 Dec; 2(3):S175-8. PubMed ID: 6242555
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
10. Behaviour of fibrinolysis in the nephrotic syndrome.
Cucuianu M; Manasia M; Spînu C; Mărcuşu C; Roman S; Comănescu A
Med Interne; 1988; 26(2):109-14. PubMed ID: 3133746
[TBL] [Abstract][Full Text] [Related]
11. [Determination of the enzyme activity of the fibrinolytic system using fibrinogen conjugated with peroxidase].
Liaginskiĭ AV; AfanasenkoGA ; Gudkova EV
Lab Delo; 1991; (11):27-31. PubMed ID: 1722843
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
13. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
[TBL] [Abstract][Full Text] [Related]
14. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
[TBL] [Abstract][Full Text] [Related]
15. [Fibrinolytic activity of the renal glomerulus. Preliminary results of a histochemical study of plasminogen activity in 44 renal biopsies].
Arrigo G; Baroni M; Benuzzi S; Bellini A; Chiesa I; Colasanti G; D'Amico G
Minerva Nefrol; 1979; 26(4):459-62. PubMed ID: 161611
[No Abstract] [Full Text] [Related]
16. Inhibition of plasminogen activator associated with chronic granulomatous inflammation.
Goldstein SM; Izaki S; Epstein WL
Thromb Res; 1979; 16(5-6):727-35. PubMed ID: 160627
[No Abstract] [Full Text] [Related]
17. Effect of caffein ingestion on plasma fibrinolytic potential.
Wojta J; Kirchheimer JC; Peska MG; Binder BR
Thromb Haemost; 1988 Apr; 59(2):337-8. PubMed ID: 3133816
[No Abstract] [Full Text] [Related]
18. [Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan].
Tomura S; Takeuchi J; Tanaka K
Nihon Jinzo Gakkai Shi; 1984 Jan; 26(1):97-121. PubMed ID: 6376892
[No Abstract] [Full Text] [Related]
19. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
[TBL] [Abstract][Full Text] [Related]
20. [Thrombolytic therapy with urokinase--indications and results].
Tilsner V
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):108-21. PubMed ID: 2427392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
